Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

ABSTRACT:

Background

There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential to cost-efficiently accelerate precision medicine trials to improve clinical efficacy and diminish costs and toxicity. However, comprehensive ctDNA profiling in metastatic prostate cancer to date has been limited.

Methods

A combination of targeted and low-pass whole genome sequencing was performed on plasma cell-free DNA and matched white blood cell germline DNA in 364 blood samples from 217 metastatic prostate cancer patients.

Results

ctDNA was detected in 85.9% of baseline samples, correlated to line of therapy and was mirrored by circulating tum

SUBMITTER: Mayrhofer M 

PROVIDER: S-EPMC6247769 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature